Eton Pharmaceuticals Inc (ETON) Price to Earnings Ratio

Corporate emblem and logo of Eton Pharmaceuticals Inc (ETON)

Eton Pharmaceuticals (ETON) focuses on developing liquid medications for children with rare pathologies, where low competition ensures sustained demand for its products. The financial model is based on the launch of already approved drugs, which minimizes the risks associated with costly research. This chart of current share prices, where the indicator stands at 37.50, is supplemented by data showing full capacity utilization of certified drug filling facilities.

Eton Corp (ETON) Price to Earnings Ratio: for the period 07/04/2022 - 11/17/2026

Comprehensive metric breakdowns and analytics for Eton Pharmaceuticals, Inc. (ETON)

General company analysis:Eton Pharmaceuticals Inc - ETON
Original product of etonpharma.com

Fundamental asset selection requires a strict alignment of market value with the actual profitability of the business. The P/E ratio measures the cost of one dollar of net income, revealing whether investor expectations are overvalued relative to actual earnings. For Eton Pharmaceuticals (ETON), this calculation is critical, as reliance on contract manufacturing organizations (CMO) directly impacts margins and bottom-line profit. Analyzing the P/E ratio history allows for an assessment of the company's capitalization resilience against operational risks.